Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Glaukos Corporation

Market Cap 7.67B 6.69B 6.19B 5.8B 10.85B 724B 10.94B 73.45B 28.46B 356B 28.79B 28.18B 1,237B P/E 2026 *
-145x
P/E 2027 * 520x
Enterprise Value 7.46B 6.51B 6.02B 5.64B 10.56B 704B 10.65B 71.46B 27.69B 347B 28.01B 27.41B 1,204B EV / Sales 2026 *
11.8x
EV / Sales 2027 * 9.21x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day+2.57%
1 week+5.17%
Current month+26.44%
1 month-8.09%
3 months+26.60%
6 months+15.43%
Current year+15.74%
1 week 125.43
Extreme 125.43
132.24
1 month 99.48
Extreme 99.48
146.71
Current year 93.96
Extreme 93.96
148.11
1 year 73.16
Extreme 73.16
148.11
3 years 59.22
Extreme 59.22
163.71
5 years 33.33
Extreme 33.33
163.71
10 years 23.08
Extreme 23.075
163.71
Manager TitleAgeSince
Chief Executive Officer 65 2000-12-31
Director of Finance/CFO 56 2022-03-31
President 50 2022-03-31
Director TitleAgeSince
Chairman 65 2021-12-30
Director/Board Member 71 2014-06-30
Director/Board Member 57 2014-06-30
Date Insider Type Main position Quantity % Market Cap.
05-27Free

Director

4,865 0.0085%
05-27Free

Director

4,865 0.0085%
05-27Free

Director

4,865 0.0085%
Change 5-day change 1-year change 3-year change Capi.($)
+2.57%+5.17%+27.69%+92.97% 7.67B
+2.21%+0.71%-17.54%+4.57% 118B
-0.66%-1.01%+5.44%-10.39% 12.72B
+0.48%-1.28%-46.91%-72.29% 4.07B
+1.51%+2.35%+18.57%+34.36% 2.56B
+0.94%+4.16%-14.60%-16.91% 1.78B
-0.21%-2.45%+2.33%-19.56% 1.59B
+5.36%+0.12%+184.99%+154.14% 1.41B
+5.37%+4.02%-28.34%-63.49% 1.26B
Average +1.95%+1.37%+14.63%+11.49% 16.78B
Weighted average by Cap. +1.94%+0.79%-11.45%+6.55%

Financials

2026 *2027 *
Net sales 631M 550M 509M 477M 892M 59.48B 900M 6.04B 2.34B 29.28B 2.37B 2.32B 102B 796M 694M 642M 602M 1.13B 75.07B 1.14B 7.62B 2.95B 36.96B 2.99B 2.92B 128B
Net income -53.86M -46.96M -43.43M -40.7M -76.2M -5.08B -76.82M -516M -200M -2.5B -202M -198M -8.69B 15.32M 13.36M 12.36M 11.58M 21.68M 1.45B 21.85M 147M 56.84M 711M 57.51M 56.27M 2.47B
Net Debt -208M -181M -168M -157M -294M -19.62B -297M -1.99B -772M -9.66B -781M -764M -33.56B -340M -296M -274M -257M -481M -32.04B -485M -3.25B -1.26B -15.78B -1.28B -1.25B -54.8B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
26-06-18 130.68 $ +2.57% 984,179
26-06-17 127.41 $ -0.09% 1,040,930
26-06-16 127.53 $ -2.01% 724,523
26-06-15 130.14 $ +2.63% 801,979
26-06-12 126.81 $ +2.05% 707,981
Trader
Investor
-
Global
-
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
130.68USD
Average target price
157.50USD
Spread / Average Target
+20.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!